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Treatment-emergent obsessive-compulsive symptoms (OCSs) have raised concern since the widespread
introduction of serotonin-dopamine antagonists (SDAs) for the treatment of schizophrenia. Further
investigations of SDA-emergent OCSs and their response to anti-obsessional agents will be beneficial
for clinicians in helping patients who suffer from this problem. We present three cases of schizophrenia
in which distressing OCSs occurred during clozapine or risperidone treatment. OCSs were assessed
consecutively using the Yale-Brown Obsessive-Compulsive Scale. The OCSs of these three patients were
responsive to anti-obsessional agents, including fluvoxamine, clomipramine, and paroxetine. We also
review the current literature and discuss the possible pathophysiology and psychopathology of SDA-
emergent OCSs.
Key Words: obsessive-compulsive symptoms, clozapine, risperidone, schizophrenia,
serotonin-dopamine antagonists
(Kaohsiung J Med Sci 2004;20:295–301)
Received: February 5, 2004     Accepted: April 2, 2004
Address correspondence and reprint requests to: Dr. Cheng-Fang
Yen, Department of Psychiatry, Kaohsiung Medical University, 100
Tzyou 1st Road, Kaohsiung 807, Taiwan.
E-mail: chfaye@cc.kmu.edu.tw
© 2004 Elsevier. All rights reserved.
Clozapine and risperidone bind strongly to serotonin (5-
HT2) and dopamine (D2) receptors, improving both the
positive and negative symptoms of schizophrenia [1].
Serotonin-dopamine antagonists (SDAs) carry a smaller
risk of extrapyramidal symptoms than dopamine recep-
tor antagonists, and eliminate the need for concurrent
anticholinergic drugs with adverse effects [2]. SDAs have
been recommended for patients with schizophrenia in
various clinical stages [3].
However, the adverse effects of SDAs reported in the
literature are numerous [1]. One of the side effects is
treatment-emergent obsessive-compulsive symptoms
(OCSs) in patients with a favorable antipsychotic response
to clozapine [4,5], risperidone [6,7], and olanzapine [8].
Although the imbalance in serotonin-dopamine neuro-
transmission with a preponderance of serotonin antago-
nism was proposed as a possible explanation of this side
effect [5,9], the causal relationship between OCSs and
SDA treatment has not been established. Few of the
case reports discuss the effects of anti-obsessional agents,
including fluvoxamine [9], sertraline [10,11], and clomipra-
mine [12], in the treatment of SDA-emergent OCSs. Fur-
ther investigation of the pathophysiology and psychopatho-
logy of treatment-emergent obsessive-compulsive fea-
tures is needed, as well as research into the pathology of
OCSs and the pharmacologic mechanisms of SDAs and
anti-obsessional agents.
We report three cases with a diagnosis of schizophre-
nia according to DSM-IV [13], in which OCSs emerged dur-
ing the course of clozapine or risperidone treatment. The
response of OCSs to anti-obsessional agents, including flu-
voxamine, clomipramine, and paroxetine, is also reported.
OCSs were assessed consecutively using the Yale-Brown
Obsessive-Compulsive Scale (YBOCS) [14] during a trial
of anti-obsessional agents with ongoing clozapine or ris-
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peridone treatment with at least a 7-month follow-up. In
current reviews, only a few case reports of OCSs have been
assessed using rating scales [8,9,12,15]. To the best of our
knowledge, this is the first report demonstrating the effica-
cy of paroxetine treatment of SDA-related OCSs in schizo-
phrenic patients. We also review the current literature and
discuss the possible pathology of SDA-emergent OCSs.
CASE PRESENTATIONS
Case 1
A 24-year-old man met the DSM-IV criteria for schizophre-
nia at the age of 19, with initial manifestations of severe
auditory and visual hallucination, disorganized speech and
behaviors, and delusions of reference and persecution.
He had been hospitalized four times in our hospital’s acute
ward, and received multiple trials of conventional anti-
psychotics, SDAs, and electroconvulsive therapy. He had
no history of obsessive-compulsive disorder (OCD) or
personality disorder (OCPD). However, during a trial of
risperidone 6 mg/day, he obsessively worried that his
father would die, and complained that he felt disgusted
while intrusive sexual images were overplayed in his
mind. Clozapine treatment was started and titrated up to
400 mg/day, with significant improvement of auditory
hallucination and delusion.
Due to a seizure attack after 17 weeks of clozapine
treatment, medication dosage was reduced to 300 mg/day.
Eight months after administration of clozapine 300 mg/
day, the patient became anxious and restless, compulsively
asked the same questions, and repeatedly asked for con-
firmation from the staff in our day hospital. He was ob-
sessed with minutiae and was often preoccupied with
thoughts of breakage of the wash basin and viral infec-
tion of his liver. He persistently requested laboratory
examinations to evaluate his liver function even after re-
assurance had been given. In addition, he worried irra-
tionally that the traffic signals might not work, and he
therefore rode a motorcycle about, checking repeatedly
to make sure that the traffic lights worked. His obsessive
and compulsive behavior caused significant distress
and impairment of his daily activities and function. For
these OCSs, clozapine was increased to 325 mg/day with
the consideration of super-sensitivity of 5-HT receptors
with long-term clozapine treatment. However, his OCSs
were not responsive to this treatment and persisted. Clo-
zapine was decreased back to 300 mg/day and fluvox-
amine treatment was added, beginning with 50 mg/day
and progressively increased to 200 mg/day in incre-
ments of 50 mg. The severity of OCSs decreased after the
initiation of fluvoxamine treatment. Fourteen weeks later,
the total YBOCS score had decreased from 32 to 1 (Fig-
ure 1). Interestingly, his obsession with viral infection of
his liver recurred when fluvoxamine was tapered to
100 mg/day. This obsessive symptom subsided again
after the dosage of fluvoxamine was increased back to
150 mg/day. Improvement of OCSs remained after 10
months’ follow-up with fluvoxamine at 150–200 mg/day.
Case 2
A 20-year-old man had a 3-year history of schizophrenia,
Figure 1. Medication dosages and Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores in Case 1.
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paranoid type, episodic with inter-episode residual symp-
toms. He presented with progressive social withdrawal,
apathy, affective flattening, poor personal care, auditory
hallucination, and delusion of persecution in the initial
episode, and he was treated using electroconvulsive therapy.
Risperidone 3 mg/day was prescribed in the following 2
years. With this treatment, he was able to join a rehabilitation
program and even obtain sheltered work. There was no
history of OCSs.
Risperidone was increased to 4 mg/day for persistent
voice commenting and delusion of reference. However, 2
weeks later, he suffered from severe egodystonic obses-
sion symptoms and was preoccupied with ruminations
about past unpleasant events. Recurrent sexual images
were experienced as intrusive. The severity of obsessive
thinking led to a trial of clomipramine 25 mg/day. Three
weeks after clomipramine was introduced, the obsessive
symptoms attenuated, with the YBOCS score decreasing
from 14 to 1. Simultaneously, risperidone was adjusted
again due to apparent positive symptoms. Unfortunately,
obsessive thinking about mistakes, with obsessive anxiety
and compulsive behaviors, developed again 2 weeks later
when the dosage of risperidone reached 6 mg/day. Paro-
xetine 20 mg/day was added to replace clomipramine, with
ongoing risperidone regimen. A marked reduction in his
obsession was found 2 weeks later (Figure 2). The substan-
tial improvement was observed at 10 months’ follow-up
with paroxetine at doses of 20–30 mg/day. However, these
obsession symptoms worsened when paroxetine was
decreased, and even relapsed transiently over a 2-month
period of treatment with paroxetine 20 mg/day.
Case 3
A 31-year-old man had been diagnosed with schizophrenia,
paranoid type, 4 years previously, with presentations of
severe auditory and visual hallucination and delusions of
persecution, reference, and grandeur for several years. He
was troubled by psychotic symptoms and reacted irritably
and violently, abusing alcohol to overcome fear and per-
ceptual disturbance. Neither a history of OCD nor OCPD
had been reported.
Risperidone was administered at 4–6 mg/day during
hospitalization 1 year ago. His condition was responsive
to the treatment but, unfortunately, he suffered from
post-psychotic depression after nearly full remission of
delusion and hallucination, under treatment with risperi-
done 4 mg/day. The depressive episode, which was care-
fully differentiated from negative symptoms and extra-
pyramidal symptoms, resolved 1 month later without any
antidepressant medication. However, he suddenly be-
came obsessive 3 months after risperidone was intro-
duced. He was totally preoccupied by the thought of his
drunken state and a past contractual obligation. He repeti-
tively talked about the same thing all day long, even af-
ter his family confirmed to him that he was not respon-
sible for this contract. He was extremely worried that he
would be arrested and jailed because he had not fulfilled
it, and he attempted suicide by drug overdose. The obses-
Figure 2. Medication dosages and Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores in Case 2.
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sive thinking persisted and was not responsive to benzo-
diazepine and paroxetine 20 mg/day over a 1-month
period. Clomipramine was started. Risperidone was with-
drawn later and olanzapine was administered. The OCSs
improved with a 3-week regimen of olanzapine 10 mg/day
and clomipramine 75 mg/day, and YBOCS score de-
creased from 39 to 5 (Figure 3). The improvement per-
sisted in the following 7 months’ follow-up. Clomipra-
mine was decreased gradually without recurrence of OCSs.
DISCUSSION
Reports of atypical antipsychotic drug-related OCSs are
mostly linked to clozapine and risperidone, and are found
in up to 10% of clozapine-treated patients [16]. A few cases
with olanzapine [8] and quetiapine [17] have also been re-
ported. All these SDAs have potent 5-HT2 and D2 antago-
nism at therapeutic doses. The hypothesis of the role that
serotonin plays in OCD was based on the observation that
treatment involves manipulating serotonin activities [18]. It
has been suggested that the anti-serotonergic effects of
SDAs are responsible for the emergence of OCSs [10].
The favorable responses of the treatment-emergent
OCSs to selective serotonin reuptake inhibitors (SSRI),
clomipramine, and potent serotonin reuptake inhibitors
further support this viewpoint.
In addition, several lines of evidence show that dopamine
is implicated in the mediation of some obsessive-compulsive
behaviors [19,20]. The importance of anatomic and function-
al interactions between serotonergic and dopaminergic
neurons must be considered. The decreases in 5-HT tonic
inhibitory influences on dopamine neurons could lead to
increased dopaminergic function due to the functional
connections between dopamine and 5-HT neurons in the
basal ganglion [19,20]. As a result, it has been postulated
that the hyperactivity of the dopaminergic system in the
striatum contributes to the rise in OCSs [12].
Norepinephrine is another member of the monoamine
system involved in the pathophysiology of OCSs [21].
Both Cases 2 and 3 experienced a clinical improvement
in OCSs with clomipramine and paroxetine treatment.
Both drugs inhibit serotonin reuptake and display po-
tent norepinephrine reuptake antagonism [19]. This in-
directly suggests that abnormalities in norepinephrine
may play a role in SDA-related OCSs.
All three cases had no history of OCD or OCPD. In
previous studies, some cases had a history of OCD [5–7,9,
22], but most had no history of OCD or OCPD [6,9,10,12,16,
18,23,24]. Remington and Adams reported that a subgroup
of schizophrenic patients who already manifest obsessive-
compulsive features as a part of their illness may be at
particular risk for treatment-emergent OCSs [22].
There may be a subset of patients vulnerable to the
development of obsessive phenomena associated with
atypical antipsychotics [6]. At high doses, SDAs block the
postsynaptic receptors in the nigrostriatal dopamine
pathway rather than mesolimbic pathway, and are, there-
fore, responsible for extrapyramidal side effects and more
commonly associated with the emergence of OCSs [19,
20]. This differential dose effect on dopamine and 5-HT
systems, along with the beneficial effect of low doses
of SDAs on refractory OCD, may indicate that the pri-
mary abnormality is in the serotonin-dopamine balance.
Figure 3. Medication dosages and Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores in Case 3.
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Greater sensitivity for the development of extrapyrami-
dal side effects in patients may be consistent with this
abnormality [6]. However, the underlying mechanisms
and risk factors are far from clear.
There is no gender prevalence in OCD [2], but SDA-
induced OCSs are more common in men according to
previous reported cases. We have reviewed 28 cases of
clozapine- or risperidone-induced OCSs [5–7,9,10,12,16,
18,22–26] reported between 1990 and 2003. There were 24
male patients and only four females [5,6,18]. Their ages
ranged from 19 to 56 years, with most patients in their
twenties or thirties. Our three cases were young male pa-
tients, which is consistent with previous studies. The effect
of gender and age factors should be further investigated.
SDA-induced OCSs seem to be dose-related. Several
case reports suggest that clozapine-induced OCSs emerge
only at doses above a certain threshold; the mean dose of
the cases in the literature is moderate to high at 454.2 ±
187.9 mg [8]. In all reported cases, the risperidone dose
exceeded 3 mg/day [6]. However, the onset of OCSs
does not seem to be predictable. Treatment-induced
OCSs emerged within weeks to months of SDA therapy
or dose increase [5–7,9,10,12,16,18,22–26]. Biondi et al
reviewed cases and reported that the latency of appear-
ance of OCSs related to the beginning of clozapine treat-
ment ranged from 2 months to 1 year [12]. In risperidone-
treated patients, the OCSs, which emerged within days to
weeks, appeared earlier than in clozapine-treated patients
[6,7,18,22,26].
Poyurovsky et al reported that OCSs appeared during
the period of clozapine dose titration in reviewed cases [16].
In certain vulnerable individuals treated chronically with
clozapine, “withdrawal” or “tardive” OCSs may develop,
possibly because of the pathophysiologic development
of a super-sensitivity in 5-HT receptors as a result of the
potent 5-HT antagonistic activity of clozapine [27].
In contrast, Poyurovsky et al also reported the dis-
appearance of OCSs in two cases during a subsequent ti-
tration of clozapine [9]. Two other patients in their report
[9] and our first case showed improvement with the
addition of fluvoxamine, which had a similar effect to the
addition of fluoxetine [9] or clomipramine [12] to cloza-
pine pharmacotherapy. However, it is likely that pa-
tients had their clozapine “dose” effectively increased
by the addition of fluvoxamine [28] due to significant
drug interaction between clozapine (metabolized through
liver P450 2D6 and IA2 isoenzymes) and fluvoxamine
(inhibition of P450 IA2) [19]. On the other hand, it may
be postulated that increasing 5-HT2/D2 antagonism
and simultaneously increasing serotonin activity im-
proves SDA-induced OCSs. Rahman et al reported that
the addition of fluvoxamine interfered with the efficacy
of clozapine, even though the plasma level was higher
[25]. Fluvoxamine is effective in risperidone-induced
OCSs [7].
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